Key information made simple
This summary needs review. Please check the official study record and contact the research team for details.

This study is completed in the United States. It is testing Manualized MDMA-Assisted Psychotherapy for PTSD.
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Then choose your country and confirm availability with each study site.
This summary needs review. Please check the official study record and contact the research team for details.
Check the official source, then confirm these points with the research team.
View official study record (opens in a new tab)Recruitment checked against the registry by HopeStage on . Registry information can change. Always confirm availability with the research team.
View official study record (opens in a new tab)The overall study status can differ from each site's status. Open a country to see its locations and their registry status.
This record does not confirm open recruitment. We can help you understand it and explore other studies.
Participation may contribute to research. Personal benefit is not guaranteed.
Ask the research team to explain the activities, time commitment, and follow-up involved.
Study sites are listed. Confirm the relevant site and any travel before making plans.
Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com
Based on the public registry summary, this study is trying to understand: The goal of this clinical trial is to learn if MDMA in combination with therapy is safe and effective in people with chronic, treatment-resistant PTSD. The main questions it aims to answer are: * Does MDMA-assisted therapy reduce PTSD symptoms? * Is there a difference in PTSD. The study team can confirm the exact objective and what it means for you.
This appears to be a medication / drug study involving Comparator Dose (40mg) MDMA HCl, Active Dose 2 (100 mg) MDMA HCl, Active Dose 1 (125 mg) MDMA HCl, Psychotherapy. Phase 2 studies usually explore whether the intervention may work, while continuing to monitor safety.
This study may concern people with ptsd; age range: Over 18 Years. The criteria appear fairly specific, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.
You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.
If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.
The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.
This study is sponsored by Resilient Pharmaceuticals, which appears to be unknown or unclear. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit me